论文部分内容阅读
目的:探讨人重组促卵泡素(rFSH)联合高纯尿促性素(HP-hMG)促排卵方案中hCG注射日血清β-hCG水平与促排卵结局的关系。方法:共129个促排周期纳入研究,其中67个长方案周期,62个拮抗剂方案周期。各个方案中,患者根据hCG注射日血清β-hCG水平分为<平均水平组和>平均水平组。结果:长方案和拮抗剂方案组的患者hCG注射日血清平均β-hCG分别为0.9mIU/ml和1.1 mIU/ml。各个方案中,<平均水平组和>平均水平组患者的临床特征、促排卵特征和获卵数、受精率、卵裂率均无统计学差异(P>0.05)。长方案中,血清β-hCG≥0.9mIU/ml的患者较<0.9 mIU/ml的患者获得可用胚胎率更高(62.1%vs 53.6%,P=0.05);拮抗剂方案中,血清β-hCG≥1.1 mIU/ml的患者较<1.1 mIU/ml的患者获得可用胚胎率更高(57.8%vs 46.7%,P=0.06)。结论:在人重组促卵泡素联合高纯尿促性素促排卵方案中注射hCG日血清β-hCG水平与可用胚胎率可能存在正相关关系。
OBJECTIVE: To investigate the relationship between serum β-hCG level and ovulation induction outcome on the day of hCG injection in rFSH and HP-hMG ovulation induction programs. Methods: A total of 129 cycles were included in the study, of which 67 were long cycles and 62 were antagonist cycles. In each protocol, patients were divided into mean level according to serum β-hCG levels on the day of hCG injection. RESULTS: The mean serum β-hCG on the day of hCG injection was 0.9 mIU / ml and 1.1 mIU / ml, respectively, in the long-term and placebo groups. In each regimen, clinical features, ovulation induction characteristics, number of oocytes retrieved, fertilization rate and cleavage rate were not statistically different (P> 0.05). In the long-term regimen, patients with serum β-hCG ≥ 0.9 mIU / ml achieved higher rates of available embryos than those with <0.9 mIU / ml (62.1% vs 53.6%, P = 0.05). In the antagonist regimen, serum β-hCG Patients with> 1.1 mIU / ml had better rates of available embryos than those with <1.1 mIU / ml (57.8% vs 46.7%, P = 0.06). Conclusion: There is a positive correlation between serum β-hCG level and available embryo rate on the day of hCG injection in human recombinant follicle stimulating hormone combined with high-purity urinary excretion of ovariectomy.